Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review

Diabetes Research and Clinical Practice

Volumn 140, Issue , 2018, Pages 118-128

  Rådholm, Karin ^a,b   Wu, Jason HY ^b   Wong, Muh Geot ^b,c   Foote, Celine ^b,d   Fulcher, Gregory ^c,e   Mahaffey, Kenneth W ^f   Perkovic, Vlado ^b   Neal, Bruce ^b,g,h  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF SYDNEY   (Australia)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Amputation; Cardiovascular disease; Diabetes type 2; Fracture; Kidney disease; Randomised controlled trials; Safety; SGLT2 inhibitors; Systematic review

Indexed keywords

SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2;

ALL CAUSE MORTALITY; AMPUTATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; FRACTURE; GENITAL TRACT INFECTION; HEART FAILURE; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; LOW RISK PATIENT; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT SAFETY; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; KIDNEY DISEASES; SODIUM-GLUCOSE TRANSPORTER 2; SURVIVAL ANALYSIS;

EID: 85045098364     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2018.03.027     Document Type: Review

References (56)

1. Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes a systematic review and meta-analysis. Ann Intern Med 159:4 (2013), 262–274.
2. Wu, J.H.Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundstrom, J., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 4:5 (2016), 411–419.
3. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:22 (2015), 2117–2128.
4. Abramson, A., Bone disturbances in injury to spinal cord and cauda equina (paraplegia): their prevention by ambulation. J Bone Joint Surg 30A (1948), 982–987.
5. U.S. Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood: Food and Drug Administration; 2015 https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm.
6. Rosenstock, J., Ferrannini, E., Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38:9 (2015), 1638–1642.
7. Taylor, S.I., Blau, J.E., Rother, K.I., Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 3:1 (2015), 8–10.
8. Bristol Myers Squibb, FDA briefing document NDA 202293 dapagliflozin oral tablets 5 AND 10 MG. 2013, United States Food and Drug Administration, USA.
9. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:7 (2017), 644–657.
10. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017.
11. Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, 2009, b2700.
12. Evaluation and Licensing Division PaFSBMoH, Labour and welfare, report on the deliberation results - ipragliflozin. 2013, Pharmaceuticals and Medical Devices Agency, Japan.
13. Evaluation and Licensing Division PaFSBMoH, Labour and welfare, report on the deliberation results - luseogliflozin. 2014, Pharmaceuticals and Medical Devices Agency, Japan.
14. Food and Drug Administration, FDA briefing document NDA 204042 invokana (canagliflozin) tablets. 2013, Food and Drug Administration, USA.
15. Boehringer Ingelheim International. Assessment report Jardiance International non-proprietary name: empagliflozin Procedure No. EMEA/H/C/002677/0000. UK: European Medicines Agency; 2014.
16. Evaluation and Licensing Division PaFSBMoH, Labour and welfare, report on the deliberation results - tofogliflozin. 2014, Pharmaceuticals and Medical Devices Agency, Japan.
17. Janssen Research & Development, Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus NDA 204042. 2013, United States Food and Drug Administration, USA.
18. Jadad, A., Moore, R., Carroll, D., Jenkinson, C., Reynolds, D., Gavaghan, D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996), 1–12.
19. Symons, M.J., Moore, D.T., Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol 55:9 (2002), 893–899.
20. 2nd ed Woodward, M., (eds.) Epidemiology: design and data analysis, 2005, Chapman and Hall/CRC Press, Boca Raton, Florida, USA.
21. Araki, E., Onishi, Y., Asano, M., Kim, H., Ekholm, E., Johnsson, E., et al. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period. J Diabetes Invest 7:4 (2016), 555–564.
22. Frias, J.P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Ohman, P., et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol, 2016 (pagination).
23. Hadjadj, S., Rosenstock, J., Meinicke, T., Woerle, H.J., Broedl, U.C., Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care 39:10 (2016), 1718–1728.
24. Haneda, M., Seino, Y., Inagaki, N., Kaku, K., Sasaki, T., Fukatsu, A., et al. Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus. Clin Ther 38:1 (2016), 88e66–88e120.
25. Heerspink, H.J., Desai, M., Jardine, M., Balis, D., Meininger, G., Perkovic, V., Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28:1 (2017), 368–375.
26. Inagaki, N., Harashima, S., Maruyama, N., Kawaguchi, Y., Goda, M., Iijima, H., Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol, 15(89), 2016.
27. Ishihara, H., Yamaguchi, S., Nakao, I., Okitsu, A., Asahina, S., Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study. Diabetes Obes Metab 18:12 (2016), 1207–1216.
28. Kadowaki, T., Inagaki, N., Kondo, K., Nishimura, K., Kaneko, G., Maruyama, N., et al. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab, 08, 2017, 08.
29. Lauring B, Eldor R, Liu J, Dagogo-Jack S, Amorin G, Johnson J, et al. Efficacy and safety of ertugliflozin in subjects with type 2 diabetes mellitus inadequately controlled on the dual combination of metformin and sitagliptin: The VERTIS SITA2 trial. In: Diabetologia. 2016; conference: 52nd annual meeting of the European association for the study of diabetes, EASD. 2016. Germany. Conference start: 20160912. Conference end: 20160916 59(1 Supplement 1):S93.
30. Leiter, L.A., Yoon, K.H., Arias, P., Langslet, G., Xie, J., Balis, D.A., et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 38:3 (2015), 355–364.
31. Li, F.F., Gao, G., Li, Q., Zhu, H.H., Su, X.F., Wu, J.D., et al. Influence of dapagliflozin on glycemic variations in patients with newly diagnosed type 2 diabetes mellitus. J Diabetes Res, 2016, 2016, 5347262.
32. Lu, C.H., Min, K.W., Chuang, L.M., Kokubo, S., Yoshida, S., Cha, B.S., Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. J Diabetes Invest 7:3 (2016), 366–373.
33. Mansfield T, Henry RR, Strange P, Zhou R, Zhuplatov SB, Klein D, et al. Effects of dapagliflozin (DAPA), a sodium glucose cotransporter 2 inhibitor, on 24-hour glycaemic control in patients with type 2 diabetes. In: Diabetologia. 2016; conference: 52nd annual meeting of the European association for the study of diabetes, EASD. 2016. Germany. Conference start: 20160912. Conference end: 20160916 59(1 Supplement 1):S339.
34. Mathieu, C., Herrera Marmolejo, M., Gonzalez Gonzalez, J.G., Hansen, L., Chen, H., Johnsson, E., et al. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52weeks in patients with type 2 diabetes. Diabetes Obes Metab 18:11 (2016), 1134–1137.
35. Petrykiv, S.I., Laverman, G.D., Zeeuw, D., Heerspink, H.J., The albuminuria lowering response to dapagliflozin is variable and reproducible between individual patients. Diabetes Obes Metab, 14, 2017, 14.
36. Rodbard, H.W., Seufert, J., Aggarwal, N., Cao, A., Fung, A., Pfeifer, M., et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab 18:8 (2016), 812–819.
37. Roden, M., Merker, L., Christiansen, A.V., Roux, F., Salsali, A., Kim, G., et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: A double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol, 14(1), 2015.
38. Rosenstock, J., Chuck, L., Gonzalez-Ortiz, M., Merton, K., Craig, J., Capuano, G., et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes. Diabetes Care 39:3 (2016), 353–362.
39. Softeland, E., Meier, J.J., Vangen, B., Toorawa, R., Maldonado-Lutomirsky, M., Broedl, U.C., Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care 40:2 (2017), 201–209.
40. Terauchi, Y., Tamura, M., Senda, M., Gunji, R., Kaku, K., Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16 week randomized, double-blind, placebo-controlled multicentre trial. Diabetes Obes Metab, 30, 2017, 30.
41. Terra, S.G., Focht, K., Davies, M., Frias, J., Derosa, G., Darekar, A., et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab, 2017 (pagination).
42. Townsend, R.R., Machin, I., Ren, J., Trujillo, A., Kawaguchi, M., Vijapurkar, U., et al. Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich, Conn) 18:1 (2016), 43–52.
43. Wan Seman, W., Rajoo, S., Mohd Noor, N., Kori, N., Sukor, N., Wahab, N.A., et al. Effects of dapagliflozin on weight loss and metabolic changes in type 2 diabetes patients fasting in the month of Ramadan. Diabetologia, 59(1 Supplement 1), 2016, S346.
44. Weber, M.A., Mansfield, T.A., Cain, V.A., Iqbal, N., Parikh, S., Ptaszynska, A., Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet 4:3 (2016), 211–220 Diabetes & Endocrinology.
45. Weber, M.A., Mansfield, T.A., Alessi, F., Iqbal, N., Parikh, S., Ptaszynska, A., Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press 25:2 (2016), 93–103.
46. Yang, W., Han, P., Min, K.W., Wang, B., Mansfield, T., T'Joen, C., et al. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial. J Diabetes 8:6 (2016), 796–808.
47. Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:4 (2016), 323–334.
48. Erondu, N., Desai, M., Ways, K., Meininger, G., Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38:9 (2015), 1680–1686.
49. Kohler, S., Zeller, C., Iliev, H., Kaspers, S., Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther 34:7 (2017), 1707–1726.
50. Watts, N.B., Bilezikian, J.P., Usiskin, K., Edwards, R., Desai, M., Law, G., et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 101:1 (2016), 157–166.
51. Roden, M., Merker, L., Christiansen, A.V., Roux, F., Salsali, A., Kim, G., et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol, 14(154), 2015.
52. Monami, M., Zannoni, S., Nreu, B., Mannucci, E., Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetol 54:4 (2017), 411–413.
53. Jardine, M.J., Mahaffey, K.W., Neal, B., Agarwal, R., Bakris, G.L., Brenner, B.M., et al. The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46:6 (2017), 462–472.
54. Yale, J.F., Bakris, G., Cariou, B., Nieto, J., David-Neto, E., Yue, D., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 16:10 (2014), 1016–1027.
55. Kohan, D.E., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:4 (2014), 962–971.
56. Barnett, A.H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H.J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes Endocrinol 2:5 (2014), 369–384.